Progesterone Enhances Sensitivity of Ovarian Cancer Cells to SN38 Through Inhibition of Topoisomerase I and Inducing Ferroptosis
Cancer Reports · 2025-04 · 8 (4)
DOI: 10.1002/cnr2.70202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 24.04.2025. Verfasst von Takahiro Koyanagi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Shimotsuke City, Tochigi, Japan. Hauptthemen laut MEDLINE: Progesterone, Ovarian Neoplasms, Irinotecan, Topoisomerase I Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Background
Progesterone rapidly induces ovarian cancer cell death through non‐genomic actions mediated by the membrane progesterone receptor (mPR).
Aims
We investigated the combined effects of progesterone and SN38, an active metabolite of irinotecan, on ovarian cancer cells. Methods and Results mPR‐positive and PR‐negative ovarian cancer cell lines were utilized in experiments. Tumor cells were exposed to SN38 or cisplatin for 48 h following exposure to progesterone for 30 min. The viable cell counts were measured using a colorimetric assay and the expression of topoisomerase I (TOPO‐I), the direct target of SN38, was observed with or without exposure to progesterone. Moreover, we investigated the relationship between several types of programmed cell death and the SN38 sensitivity enhancement effect of progesterone using specific cell death inhibitors. The chemosensitivity to SN38 was 8.7‐ to 26.0‐fold higher with the administration of progesterone than that without ( p < 0.01), but not to cisplatin in ovarian cancer cells. Progesterone suppressed the expression of TOPO‐I mRNA by less than 50% ( p < 0.01). Furthermore, among various programmed cell death inhibitors, only the ferroptosis inhibitor attenuated the progesterone‐induced SN38 chemosensitivity enhancement effect.
Conclusions
Progesterone increased sensitivity to SN38 by suppressing TOPO‐I expression and inducing ferroptosis. The combination of progesterone and irinotecan could be a novel treatment modality for ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Shimotsuke City, Tochigi, Japan.
- Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke City, Tochigi, Japan.
ORCID-Profile: Takahiro Koyanagi
Förderung
- JSPS KAKENHI
Zitieren
APA
Koyanagi, T., Saga, Y., Takahashi, Y., Tamura, K., Suizu, E., Takahashi, S., Taneichi, A., Takei, Y., Mizukami, H., & Fujiwara, H. (2025). Progesterone Enhances Sensitivity of Ovarian Cancer Cells to SN38 Through Inhibition of Topoisomerase I and Inducing Ferroptosis. Cancer Reports, 8(4). https://doi.org/10.1002/cnr2.70202
Vancouver
Koyanagi T, Saga Y, Takahashi Y, Tamura K, Suizu E, Takahashi S, et al. Progesterone Enhances Sensitivity of Ovarian Cancer Cells to SN38 Through Inhibition of Topoisomerase I and Inducing Ferroptosis. Cancer Reports. 2025;8(4). doi:10.1002/cnr2.70202
BibTeX
@article{Koyanagi2025,
author = {Koyanagi, Takahiro and Saga, Yasushi and Takahashi, Yoshifumi and Tamura, Kohei and Suizu, Eri and Takahashi, Suzuyo and Taneichi, Akiyo and Takei, Yuji and Mizukami, Hiroaki and Fujiwara, Hiroyuki},
title = {Progesterone Enhances Sensitivity of Ovarian Cancer Cells to SN38 Through Inhibition of Topoisomerase I and Inducing Ferroptosis},
journal = {Cancer Reports},
year = {2025},
volume = {8},
number = {4},
doi = {10.1002/cnr2.70202}
}
EUVIMED